Elsevier launches EmBiology to deliver the unparalleled insights into biological activities that accelerate drug discovery

Elsevier, a leader in global information analytics, has launched EmBiology, a research tool that visualizes a comprehensive landscape of biological relationships, empowering researchers to gain a rapid understanding of disease biology and focus on critical evidence. Like Elsevier’s medical research database Embase, EmBiology extracts and delivers information from Elsevier content and third-party publishers. Powered by Elsevier’s Biology Knowledge Graph, EmBiology draws on more than 7.2 million full-text journal articles, 34.5 million abstracts and 430,000 clinical trials. Researchers working in drug discovery and development will be able to intuitively explore biological relationships and concepts to improve drug target and biomarker identification and prioritization. The depth and reliability of EmBiology’s data will enable more confident decision making about what targets to pursue and how to modulate the disease process.

“Researchers at pharmaceutical companies are faced with the monumental task to uncover insights from overwhelming amounts of information to identify new, more effective therapies. Intense competition demands that insights are identified quickly and confidently; researchers need to be equipped with data skills to do that,” comments Dr. Sherry Winter, Director of Biology and Biomedical Solutions at Elsevier. “EmBiology relieves this pressure by collating critical disease data into a single place and structuring it in an interactive way. This facilitates evidence-based research decisions for successful projects that ultimately bring novel treatments to patients faster.”

EmBiology surfaces relationship information, including directionality and effect, for a wide range of subject areas including expression, biomarkers and regulation. Elsevier automates data curation with technology that transforms unstructured text into structured information. The resulting knowledge graph includes 1.4 million entities connected by 15.7 million relationships to enable deep insights from a broad range of literature, with more added weekly, so researchers can be confident they are always viewing the latest concepts and terms. Results are displayed in a Sankey diagram that visually facilitates understanding of disease development, progression and drug responsiveness, whatever the researchers’ level of data skills. Users can also apply filters to narrow down their research questions and rapidly confirm their experimental hypotheses for new drug targets, biomarkers and drug repurposing projects.

“Elsevier has a longstanding reputation as a leader in managing and disseminating scientific information and classifying life science data,” continues Dr. Winter. “A team of subject matter experts developed and refined our Biology Knowledge Graph over a period of more than 20 years. EmBiology is built on this powerful data model, so that researchers can get precise answers to their questions without worrying about structuring data.”

Sobre a Elsevier

A Elsevier é líder global em informação avançada e suporte à tomada de decisão. Por mais de um século, ajudou a avançar a ciência e a saúde para promover o progresso humano. Apoia comunidades de pesquisa acadêmicas e corporativas, médicos, enfermeiros, futuros profissionais de saúde e educadores em 170 países, fornecendo conhecimentos críticos e soluções inovadoras que combinam conteúdo científico e médico confiável com tecnologias de IA de ponta. A Elsevier promove inclusão e sustentabilidade, incorporando esses valores em seus produtos e cultura. A Elsevier Foundationopens in new tab/window apoia pesquisas e parcerias de saúde ao redor do mundo.

A Elsevier faz parte da RELXopens in new tab/window, fornecedora global de ferramentas de análise e decisão baseadas em informação para clientes profissionais e empresariais. Para mais informações, visite www.elsevier.com e siga-nos nas redes sociais: @ElsevierConnect e @ElsevierPesquisa.